Drug Trial Radar · NCT00160121
Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease
Last checked: Nov 20, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,500
Actual
Start
Jan 10, 2005
Primary completion
Dec 13, 2005
Study completion Dec 13, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test how well lanthanum carbonate reduces the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease and to determine the patient and physician's satisfaction.
Conditions
- Kidney Failure, Chronic
Interventions
Lanthanum carbonateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-dialysis serum phosphorus levels at 12 weeksTime frame: Week 12
- Patient satisfaction questionnaire at 12 weeksTime frame: Week 12
- Physician satisfaction questionnaire at 12 weeksTime frame: Week 12
- Patient preference questionnaire at 12 weeksTime frame: Week 12
- Physician preference questionnaire at 12 weeksTime frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.